AMERICAN PHARMACEUTICAL ASSOCIATION
The National Professional Society of Pharmacists

February 27, 1974

Honorable Gaylord Nelson
Chairman, Subcommittee on
Monopoly
Senate Select Committee on
Small Business
Room 424
Old Senate Office Building
Washington, DC 20510

Dear Senator Nelson:

This will respond to your request that I supplement my letter to you of February 25, 1974, with a review and analysis of the second increment of information sent to you by the Department of Defense.

In view of the fact that this information was only recently received in this office, coupled with the fact that you have requested my response promptly, my analysis of necessity has had to be both concise and relatively general. In the event that a more detailed response -- even on an item-by-item basis -- is desired, I will undertake to provide such an effort at your additional request.

Turning to the specific material provided by DOD, the data under "tab A" and "tab B" all appear to pertain to matters about which I did not comment in my February 25 analysis. Consequently, I have no comments relative to these sections. On the other hand, the information provided under "tab C" does contain supplemental information relative to one question about which I had commented earlier; namely, question 15(e), in which you had requested that DOD-DPSC name the products for which additional specifications have been developed by them, and that they indicate the significance and purpose of these extra requirements.

In essence, the DOD in its original response dated January 30, had provided a representative sampling of drug items along with the so-called "additional requirements" they have developed and applied to these drug items. In testifying before the

2215 CONSTITUTION AVENUE, N.W., WASHINGTON, D.C. 20037 • (202) 628-4410
CABLE ADDRESS: AMPHARMA